Relaxant Effects of the Selective Estrogen Receptor Modulator, Bazedoxifene, and Estrogen Receptor Agonists in Isolated Rabbit Basilar Artery

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Arduini A

Grupos

Abstract

We have previously shown that the selective estrogen receptor modulator, bazedoxifene, improves the consequences of ischemic stroke. Now we aimed to characterize the effects and mechanisms of action of bazedoxifene in cerebral arteries. Male rabbit isolated basilar arteries were used for isometric tension recording and quantitative polymerase chain reaction. Bazedoxifene relaxed cerebral arteries, as 17-beta-estradiol, 4,4',4 ''-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol [estrogen receptor (ER) alpha agonist], and G1 [G protein-coupled ER (GPER) agonist] did it (4,4',4 ''-(4-propyl-[ 1H]-pyrazole-1,3,5-triyl)trisphenol > bazedoxifene = G1 > 17-beta-estradiol). 2,3-Bis(4-hydroxyphenyl)-propionitrile (ER beta agonist) had no effect. Expression profile of genes encoding for ER alpha (ESR1), ER beta (ESR2), and GPER was GPER > ESR1 > ESR2. As to the endothelial mechanisms, endothelium removal, N-G-nitro-L-arginine methyl ester, and indomethacin, did not modify the relaxant responses to bazedoxifene. As to the K+ channels, both a high-K+ medium and the K-v blocker, 4-aminopyridine, inhibited the bazedoxifene-induced relaxations, whereas tetraethylammonium (nonselective K+ channel blocker), glibenclamide (selective K-ATP blocker) or iberiotoxin (selective K-Ca blocker) were without effect. Bazedoxifene also inhibited both Ca2+- and Bay K8644-elicited contractions. Therefore, bazedoxifene induces endothelium-independent relaxations of cerebral arteries through (1) activation of GPER and ER alpha receptors; (2) increase of K+ conductance through K-v channels; and (3) inhibition of Ca2+ entry through L-type Ca2+ channels. Such a profile is compatible with the beneficial effects of estrogenic compounds (eg, SERMs) on vascular function and, specifically, that concerning the brain. Therefore, bazedoxifene could be useful in the treatment of cerebral disorders in which the cerebrovascular function is compromised (eg, stroke).

Datos de la publicación

ISSN/ISSNe:
0160-2446, 1533-4023

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY  LIPPINCOTT WILLIAMS & WILKINS

Tipo:
Article
Páginas:
313-321
Factor de Impacto:
0,939 SCImago
Cuartil:
Q2 SCImago

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • bazedoxifene; calcium channels; cerebral arteries; estrogen receptors; potassium channels; selective estrogen receptor modulators

Campos de estudio

Proyectos asociados

INVESTIGACION EN RED DE LAS ENFERMEDADES NEUROLOGICAS

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

C03/06 . INSTITUTO DE SALUD CARLOS III . 2003

RED DE INVESTIGACION (RENEVAS)

Investigador Principal: ENRIQUE ALBORCH DOMÍNGUEZ

RD06/0026/0006 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006

RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010

MICROCLUSTERS-CALIDAD, SEGURIDAD Y FUNCIONALIDAD DE ALIMENTOS

Investigador Principal: JOSÉ LUIS MULLOR SANJOSÉ

2011_0171_VLC/CAMPUS_MCI_MULLOR_SALOM . 2011

INFLUENCIA DE LA DIABETES SOBRE LAS VIAS DE SEÑALIZACION DE LOS RECEPTORES ESTROGENICOS CEREBRALES EN EL ICTUS ISQUEMICO AGUDO EXPERIMENTAL: IMPLICACIONES TERAPEUTICAS

Investigador Principal: GERMÁN TORREGROSA BERNABÉ

PI12/00145 . INSTITUTO DE SALUD CARLOS III . 2013

ENFERMEDADES VASCULARES CEREBRALES (ICTUS)

Investigador Principal: JUAN BAUTISTA SALOM SANVALERO

RD12/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

IDENTIFICACION DE NUEVAS MOLECULAS CON ACTIVIDAD ANTICOAGULANTE Y/O CITOPROTECTORA EN LA VIA DE LA PROTEINA C: EXPLORANDO SU UTILIDAD CLINICA.

Investigador Principal: SILVIA NAVARRO ROSALES

PI14/00512 . INSTITUTO DE SALUD CARLOS III . 2015

EFECTO DE UN HIDROLIZADO DE LACTOFERRINA BOVINA SOBRE LA PRESIÓN ARTERIAL EN SUJETOS PREHIPERTENSOS Y LEVEMENTE HIPERTENSOS NO MEDICADOS. / EFFECT OF A BOVINE LACTOFERRIN HYDROLYSATE ON BLOOD PRESSURE IN PREHYPERTENSIVE AND MILDLY HYPERTENSIVE NON-MEDICATED SUBJECTS.

2014_0385_CRC_SALOM . 2014

NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMÉDICO

Investigador Principal: JUAN BAUTISTA SALOM SANVALERO

MAT2015-64139-C4-1-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2016

Cita

Compartir